Early this morning we announced an initiative to deliver and enhance a minimally invasive circulating tumor DNA (ctDNA) test to cancer patients across Canada in response to COVID-19. Thousands have been adversely affected since the pandemic forced health systems to delay or cancel surgeries including tissue biopsies.

Supported by the Digital Technology Supercluster, Project ACTT – Access to Cancer Testing & Treatment in Response to COVID-19 makes testing immediately available to 2,000 patients with lung, breast, or colorectal cancer in Canada. We are honoured to lead this project in partnership with Queen’s University, AstraZeneca Canada, the Eastern Ontario Regional Laboratory Association, Genolife, Semaphore Solutions, emtelligent, Xtract AI, Novateur, and Illumina. 

Working with this impressive roster, we will also enhance the ctDNA solution to detect a broader range of cancer types, increasing the potential reach from 40,000 to 70,000 cancer patients each year in Canada alone. Further, the project will generate the data required to determine if this testing can be delivered under provincial health coverage — making it possible to conduct tests in-house at Canadian hospitals and labs, increasing availability in remote and rural areas, and future-proofing against COVID-19 and other pandemics. 

Read more about Project ACTT in today’s press release.

Learn more about how to get tested


Today also marks another important milestone for our company.

Over the past year, we have grown our commercial team, welcomed new customers and collaborators, and are on the path to fundamentally change how patients and oncologists gain information about cancer treatment selection. During this time, we have also heard from prospective partners, oncologist groups, and patients that our company name did not fully communicate our expertise beyond genomics. We thus embarked on a journey to identify a corporate name reflective of our work today and our strategic vision for the future.

As of today, our company is now Canexia Health

Canexia Health represents our deep focus on cancer patients, our commitment to exacting knowledge, and the community nexus we are building with partners to make precision oncology affordable and accessible. What has changed? Our name, logo, and visual assets including our newly refreshed website. Our mission remains, and there is no impact on how we operate. 

More to come in the coming weeks on this exciting new chapter. In the meantime, visit us at www.canexiahealth.com.



Recent Resources


January 11, 2021

Canadian Program to Deploy Cancer Testing During COVID-19 Reaches Key Milestones, Adds New Partners

With a strategic investment from Canada’s Digital Technology Supercluster, Project ACTT is speeding up cancer testing for targeted treatment selection during the pandemic through a minimally invasive circulating tumor (ctDNA) DNA test, which is available as an alternative to some surgical tissue biopsies for patients with advanced lung, breast, or colorectal cancer.


December 16, 2020

How to Ensure Equitable Access to Cancer Treatment Selection During and Beyond COVID-19

Earlier this year, Canexia Health launched Project ACTT, Access to Cancer Testing & Treatment in Response to COVID-19, with support from the Canadian federal government via the Digital Technology Supercluster. Through ACTT, we are leading a consortium of partners to speed up cancer testing in Canada for targeted treatment selection during the pandemic through minimally invasive circulating tumor (ctDNA) testing.